Quinten Health Partners with Certara to Advance Precision Medicine and Health Economics

2021, 27 May

| 2 min read|
Grégoire Dugast

Paris, May 27, 2021 – Quinten Health today announced that it is collaborating with Certara, Inc. to offer a unique end-to-end suite of technology-enabled services to biopharmaceutical companies for more agile data-driven R&D and market access.

As precision care and digital healthcare become a reality, the pharmaceutical industry needs to reinvent the way drugs are developed and marketed with more agility and better anticipation of their real-world value.

Through this partnership, Quinten Health, along with Certara, is providing integrated pharmacometrics, health economics and machine learning (ML)/artificial intelligence (AI) technologies applied to help pharmaceutical companies design better and faster trials and develop portfolio and access strategies, leveraging both trial and real-world data.

Certara and Quinten Health bring the best of the two worlds. Certara has the strongest and largest pool of pharmacometrics and health economic modelers and tools. Our AI/ML algorithms will help integrating both biological and economic data to support real-time decision making” says Dr. Billy Amzal, CEO of Quinten Health.

Quinten Health specializes in interpretable real-world data science, ML/AI and natural language processing applied to biomedical literature. For example, Quinten Health performs high-performance patient profiling with Q-Finder®, a proprietary machine learning algorithm designed to identify and characterize high-value sub-groups. Q-Finder® has proven to be instrumental in, for example, drug responders identification or fast progressors profiling. See Quinten Health website for more details. This expertise, combined with Certara’s pioneering work in the area of health outcomes prediction under real-world conditions, enables improved models, and importantly, more precise and more timely predictions.

Quinten Health’s partnership with Certara will enable the healthcare ecosystem to accelerate time to market and de-risk strategic decisions by generating integrative real-world evidence and in silico realworld impact simulations.


latest articles

Thumbnail presenting format and title of the article "A natural language processinf approach to automate Patients' testimonials analysis"
2022, 24 November

Discover our new work around patients’ perce...

The poster "𝘼 𝙉𝙖𝙩𝙪𝙧𝙖𝙡 𝙇𝙖𝙣𝙜𝙪𝙖𝙜𝙚 𝙋𝙧𝙤𝙘𝙚𝙨𝙨𝙞𝙣𝙜 (#𝙉𝙇𝙋) 𝘼𝙥𝙥𝙧𝙤𝙖𝙘𝙝 𝙩𝙤 𝘼𝙪𝙩𝙤𝙢𝙖𝙩𝙚 𝙋𝙖𝙩𝙞𝙚𝙣𝙩𝙨’ 𝙏𝙚𝙨𝙩𝙞𝙢𝙤𝙣𝙞𝙖𝙡𝙨 𝘼𝙣𝙖𝙡𝙮𝙨𝙞𝙨" was written in collaboration with Mélissa...